CRON Q2 2023 Earnings — Cronos Group Inc. Revenue & Financial Results | Market Cap Arena

CRONCronos Group Inc.

$983M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$19M-31.6% YoY

Gross Profit

$3M16.3% margin

Operating Income

-$21M-108.4% margin

Net Income

-$8M-44.0% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$42M

Stockholders' Equity

$1.5B

Cash & Equivalents

$542M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$28M	-31.6%
Gross Profit	$3M	$6M	-44.3%
Operating Income	-$21M	-$33M	+36.7%
Net Income	-$8M	-$26M	+67.9%

Revenue Segments

Cannabis Flower

$14M74%

Cannabis Extracts

$5M26%

Product and Service, Other

$81,0000%

Geographic Segments

CANADA

$14M71%

ISRAEL

$5M29%